ABVC Financial Statements From 2010 to 2025

ABVC Stock  USD 3.35  0.23  6.42%   
ABVC Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ABVC Biopharma's valuation are provided below:
Gross Profit
507.9 K
Market Capitalization
56.9 M
Enterprise Value Revenue
115.7422
Revenue
508.4 K
Earnings Share
(0.19)
We have found one hundred twenty available fundamental signals for ABVC Biopharma, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of ABVC Biopharma's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable for few more years. As of July 20, 2025, Market Cap is expected to decline to about 8 M. In addition to that, Enterprise Value is expected to decline to about 10.4 M

ABVC Biopharma Total Revenue

535,067

Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 867.2 K, Selling General Administrative of 4.9 M or Total Revenue of 535.1 K, as well as many indicators such as Price To Sales Ratio of 13.67, Dividend Yield of 0.0 or PTB Ratio of 5.67. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
  
Build AI portfolio with ABVC Stock
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

ABVC Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM7.5 M4.7 M
Slightly volatile
Short and Long Term Debt Total1.9 M2.4 M1.8 M
Slightly volatile
Total Current Liabilities6.9 M6.6 M3.3 M
Slightly volatile
Common Stock Shares Outstanding12.3 M11.7 M2.8 M
Slightly volatile
Liabilities And Stockholders EquityM7.5 M4.7 M
Slightly volatile
Non Current Liabilities Total245.6 K258.5 K451.2 K
Slightly volatile
Other Stockholder Equity73.2 M69.7 M27 M
Slightly volatile
Total Liabilities7.2 M6.8 M3.7 M
Slightly volatile
Total Current Assets1.4 M2.2 M1.6 M
Slightly volatile
Other Current Liabilities2.2 M3.9 M2.3 M
Slightly volatile
Current Deferred Revenue85.2 K81.1 K24.9 K
Slightly volatile
Cash236 K248.4 K720.5 K
Pretty Stable
Cash And Short Term Investments297.5 K313.1 K744.8 K
Slightly volatile
Common Stock13.2 K13.9 K50.5 K
Pretty Stable
Net Receivables681.1 K1.2 M488.1 K
Slightly volatile
Property Plant And Equipment Net1.4 M1.2 M1.3 M
Slightly volatile
Non Current Assets Total3.7 M5.4 M3.5 M
Slightly volatile
Property Plant And Equipment Gross4.7 M4.5 MM
Slightly volatile
Capital Stock13.2 K13.9 K129.1 K
Slightly volatile
Capital Lease Obligations852.7 K640.4 K756.6 K
Slightly volatile
Non Current Liabilities Other15.4 K24.9 KK
Slightly volatile

ABVC Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.9 MM4.2 M
Slightly volatile
Total Revenue535.1 K509.6 K234.8 K
Slightly volatile
Other Operating Expenses4.2 M5.2 M4.2 M
Slightly volatile
Cost Of Revenue72576354.2 K
Slightly volatile
Total Operating Expenses4.1 M5.2 M4.2 M
Slightly volatile
Depreciation And Amortization190.9 K200.9 K874 K
Very volatile
Selling And Marketing Expenses24.4 K25.7 KM
Slightly volatile
Research Development170.3 K179.3 K5.1 M
Slightly volatile
Interest Income73.2 K87.4 K42.1 K
Slightly volatile
Reconciled Depreciation211 K200.9 K61 K
Slightly volatile

ABVC Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow878 K863.8 KM
Slightly volatile
Stock Based Compensation2.1 M2.8 M1.7 M
Slightly volatile
Issuance Of Capital Stock29.5 K31 K2.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.6714.384343 K
Pretty Stable
Days Sales Outstanding608829709
Slightly volatile
Average Payables20.1 K21.2 K31.4 K
Slightly volatile
Stock Based Compensation To Revenue11.7212.342.6 K
Pretty Stable
Capex To Depreciation0.810.851.49
Pretty Stable
EV To Sales17.7418.673242.7 K
Pretty Stable
Payables Turnover0.890.930.5405
Slightly volatile
Sales General And Administrative To Revenue9.49.894944 K
Slightly volatile
Research And Ddevelopement To Revenue0.330.352347.1667
Slightly volatile
Capex To Revenue0.150.161.0982
Slightly volatile
Cash Per Share0.0240.025296.67
Slightly volatile
Days Payables Outstanding38440465.9 K
Slightly volatile
Intangibles To Total Assets0.520.850.8665
Pretty Stable
Current Ratio0.320.33240.574
Pretty Stable
Receivables Turnover0.420.44053.5161
Slightly volatile
Capex Per Share0.00530.005659.6835
Slightly volatile
Average ReceivablesM957.3 K449.4 K
Slightly volatile
Revenue Per Share0.04310.0418.5934
Slightly volatile
Interest Debt Per Share0.250.26252.5 K
Slightly volatile
Debt To Assets0.310.32241.4585
Slightly volatile
Graham Number15.4217.3518.9126
Slightly volatile
Days Of Payables Outstanding38440465.9 K
Slightly volatile
Ebt Per Ebit1.051.14121.477
Very volatile
Net Income Per E B T1.160.91310.9908
Very volatile
Cash Ratio0.0360.03790.3753
Very volatile
Days Of Sales Outstanding608829709
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.0239
Slightly volatile
Fixed Asset Turnover0.460.44190.1853
Slightly volatile
Debt Ratio0.310.32241.4585
Slightly volatile
Price Sales Ratio13.6714.384343 K
Pretty Stable
Asset Turnover0.06140.06750.04
Slightly volatile

ABVC Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM8.4 M102.9 M
Very volatile
Enterprise Value10.4 M10.9 M105 M
Very volatile

ABVC Fundamental Market Drivers

Cash And Short Term Investments313.1 K

ABVC Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ABVC Biopharma Financial Statements

ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue81.1 K85.2 K
Total Revenue509.6 K535.1 K
Cost Of Revenue 763.00  724.85 
Stock Based Compensation To Revenue 12.34  11.72 
Sales General And Administrative To Revenue 9.89  9.40 
Research And Ddevelopement To Revenue 0.35  0.33 
Capex To Revenue 0.16  0.15 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(9.25)(9.71)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.19)
Revenue Per Share
0.039
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.11)
Return On Equity
(0.42)
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.